Alert (Alert)
Vigafyde Solution
Product Images NDC 80789-003
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 18 technical images submitted to the FDA as part of the official labeling for Vigafyde (NDC 80789-003). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Upsher-smith Laboratories, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Ndc 80789-003-15 (Carton Label)
Figure A (Figure A)
Figure B (Figure B)
This text describes the components of an oral syringe, including the barrel, dose markings, plunger, stopper, ribbed end, plunger bottle adapter, and the syringe itself. These parts are essential for accurate and precise administration of liquid medication.*
Figure C (Figure C)
This text appears to mention an oral syringe with an adapter shown in Figure C. It seems to be a part of a set of instructions or a product manual related to the assembly or use of the oral syringe.*
Figure D (Figure D)
Figure E (Figure E)
Not available.*
Figure F (Figure F)
This text mentions a "Bottle Adapter" at position 0 on the neck of a bottle. It also contains a reference to "Figure F", suggesting it may be part of a set of instructions or illustrations.*
Figure G (Figure G)
Figure H (Figure H)
Figure I (Figure I)
Figure J (Figure J)
Figure K (Figure K)
Figure L (Figure L)
Figure M (Figure M)
Figure N (Figure N)
All People Who Take Vigafyde (Med Guide Box)
This text provides important information for caregivers of babies taking VIGAFYDE. It highlights the risk of permanent vision loss associated with any amount of VIGAFYDE, with higher risks linked to increased daily intake and longer duration of use. The text also notes that it is not possible to predict when vision loss may occur, as it could happen at any point during treatment, including after discontinuation. Vigilance and communication with healthcare providers are crucial for monitoring and addressing potential vision issues in infants taking VIGAFYDE.*
Structural Formula For Vigabatrin (Vigabatrin Structure)
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
